A pooled analysis by the FDA, which included 11,955 patients across 12 neoadjuvant trials, demonstrated that pCR was correlated with favorable event-free survival (EFS) and overall survival (OS), particularly in HER2+, hormone receptor-negative BC [3]. The gene discussed is ERBB2; the disease is breast cancer.